TABLE 2.
Study | CircRNA expression | CircRNA type | Expression level | Test method | Reference gene | Survival point | Follow‐up time | HR extraction | |
---|---|---|---|---|---|---|---|---|---|
High | Low | ||||||||
Chen B 2018 20 | 83 | 157 | circEPSTI1 | Up‐regualted | qRT‐PCR | β‐actin | OS, DFS | Unclear | Indirectly |
Zeng K 2018 34 | 82 | 83 | circANKS1B | Up‐regualted | qRT‐PCR/2−△△Ct method | GAPDH | OS | Mentioned the follow‐up process | Directly |
He R 2017 22 | 119 | 103 | circGFRA1 | Up‐regualted | qRT‐PCR/2−△△Ct method | β‐actin | OS, DFS | Unclear | Indirectly |
Yang L 2019 31 | 29 | 28 | Circ_0103552 | Up‐regualted | qRT‐PCR/ΔCt | Unclear | OS | Unclear | Directly |
Uhr K 2018 27 | Total: 345 | CDR1‐AS | Up‐regualted | qRT‐PCR/2−△△Ct method | Unclear | OS, PFS | Median: 91 mo | Directly | |
Xu JH 2019 29 | 75 | 70 | has_circ_001569 | Up‐regualted | qRT‐PCR/2−△△Ct method | GAPDH | OS | Unclear | Directly |
Liu Z 2019 24 | 38 | 98 | hsa_circ_001783 | Up‐regualted | qRT‐PCR | β‐actin | OS | Unclear | Directly |
Zhou H 2019 35 | 85 | 65 | circFBXL5 | Up‐regualted | Microarray analysis | / | OS | Unclear | Indirectly |
Xu Y 2018 30 | 41 | 35 | circ_0005230 | Up‐regualted | qRT‐PCR/2−△△Ct method | GAPDH | OS | Unclear | Directly |
Yang R 2019 32 | 20 | 20 | circAGFG1 | Up‐regualted | qRT‐PCR | Unclear | OS | Unclear | Directly |
Wang S 2018 28 | 39 | 39 | circ‐UBAP2 | Up‐regualted | qRT‐PCR/2−△△Ct method | GAPDH, U6 | OS | Unclear | Indirectly |
Gao D 2019 21 | 49 | 48 | circ_0006528 | Up‐regualted | qRT‐PCR/2−△△Ct method | Unclear | OS, RFS | Unclear | Indirectly |
Smid M 2019 26 | Total: 348 | circCNOT2 | Up‐regualted | qRT‐PCR/2−△△Ct method | Unclear | PFS | Unclear | Directly |
Abbreviations: DFS, disease‐free survival; GAPDH, reduced glyceraldehyde‐phosphate dehydrogenase; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; qRT‐PCR, quantitative reverse transcription‐polymerase chain reaction; RFS, relapse‐free survival.